Introduction

Author  TOP

John G. Bartlett, MD
Professor of Medicine
Chief, Division of Infectious Diseases
Director, AIDS Service
The Johns Hopkins University School of Medicine
Baltimore, Maryland

References  TOP

The (DHHS) Guidelines for the Use of Antiretroviral Agents in
HIV-Infected Adults and Adolescents. (The Living Document: October 6, 2005).

2001 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus. November 28, 2001.

USPHS/IDSA. Treating Opportunistic Infections Among HIV-Infected Adults and Adolescents . MMWR Recommendations and Reports 53 (RR15):1-112, December 17, 2004.

Public Health Service Task Force Recommendations for the Use of Antiretroviral Drugs in Pregnant HIV-1 Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States. June 23, 2005.

ATS/CDC Statement on Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection. MMWR Recommendations and Reports Vol. 49, No. RR-6, June 9, 2000.

Incorporating HIV Prevention into the Medical Care of Persons Living with HIV: Recommendations of CDC, the Health Resources and Services Administration, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recommendations and Reports, Vol. 52, No. RR-12, July 18, 2003.

Integrating Nutrition Therapy into Medical Management of Human Immunodeficiency Virus. Clin Infect Dis 2003; 36; Suppl 2:S51-109.

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis, Am J Respir Crit Care Med 2003;167(4):603.

Updated US Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis. MMWR 2005; 54:RR-9.

Antiretroviral Postexposure Prophylaxis After Sexual, Injection-Drug Use, or Other Nonoccupational Exposure to HIV in the United States: Recommendations from the U.S. Department of Health and Human Services. MMWR 2005; 54:RR-2.

Important Information for Users of This Pocket Guide  TOP

This document is provided as an information resource for physicians and other health care professionals to guide them in the appropriate treatment of patients with HIV/AIDS. Recommendations for care and treatment change rapidly, and opinions can be controversial; therefore, physicians and other health care professionals are encouraged to consult other sources, especially manufacturers’ package inserts, and confirm the information contained in these tables. The individual physician or other health care professional should use his/her best medical judgment in determining appropriate patient care or treatment because no single reference or service can take the place of medical training, education, and experience. Although these tables have been carefully prepared and reviewed, the author makes no warranty as to the reliability, accuracy, timeliness, usefulness, or completeness of the information. The data presented herein are for informational purposes only. Determination of appropriate treatment is the responsibility of the treating physician.

Abbreviations Used in This Pocket Guide  TOP

Drug Abbreviations

ABC: abacavir (Ziagen)
APV: amprenavir ( Agenerase )
ATV: atazanavir (Reyataz)
AZT: zidovudine (Retrovir)
CBV: Combivir (AZT+3TC)
ddI: didanosine (Videx)
d4T: stavudine (Zerit)
ddC: zalcitabine (Hivid)
DLV: delavirdine (Rescriptor)
EFV: efavirenz (Sustiva)
ENF: enfuvirtide (Fuzeon, T-20)
FTC: emtricitabine (Emtriva)
FTV: Fortovase (saquinavir, soft gel cap)
FPV: fosamprenavir (Lexiva)
HU: hydroxyurea
IDV: indinavir (Crixivan)
INH: isoniazid
INV: Invirase (saquinavir, hard gel cap)
IVIG: intravenous immune globulin
LPV/r: lopinavir/ritonavir (Kaletra)
NFV: nelfinavir (Viracept)
NNRTI: non-nucleoside reverse transcriptase inhibitor
NRTI: nucleoside reverse transcriptase inhibitor
NVP: nevirapine (Viramune)
PI: protease inhibitor
RBT: rifabutin (Mycobutin)
RTV: ritonavir (Norvir)
r: ritonavir in dose <400 mg/day
SQV: saquinavir (Invirase, Fortovase)
TPV: tipranavir (Artivus)
3TC: lamivudine (Epivir)
T-20: enfuvirtide (Fuzeon)
TDF: tenofovir (Viread)
TMP-SMX: trimethoprim sulfamethoxazole
TZV: Trizivir (ABC+AZT+3TC)
VZIG: varicella zoster immune globulin
ZDV: zidovudine (Retrovir)

Miscellaneous Abbreviations

ART: antiretroviral therapy
EC: enteric coated
HAART: highly active antiretroviral therapy
IV: intravenous
IM: intramuscular
VL: viral load
bid: twice per day
biw: twice per week
CNS: central nervous system
hs: bedtime (hour of sleep)
mo: month
po: by mouth
q: every
qd: daily
qid: four times per day
qm: monthly
qod: every other day
qw: every week
soln: solution
tid: three times per day
tiw: three times per week
TAMS: thymidine analogue assoc. mutations
ULN: upper limit of normal